BB&T Corp cut its position in Allergan PLC. (NYSE:AGN) by 20.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,667 shares of the company’s stock after selling 1,922 shares during the period. BB&T Corp’s holdings in Allergan PLC. were worth $1,864,000 at the end of the most recent quarter.
Other hedge funds have also added to or reduced their stakes in the company. Crestwood Advisors Group LLC purchased a new stake in Allergan PLC. during the first quarter worth about $103,000. Feltz Wealth PLAN Inc. bought a new position in Allergan PLC. during the first quarter valued at $107,000. Enterprise Financial Services Corp increased its stake in Allergan PLC. by 62.7% in the first quarter. Enterprise Financial Services Corp now owns 462 shares of the company’s stock valued at $110,000 after buying an additional 178 shares in the last quarter. Jacobi Capital Management LLC increased its stake in Allergan PLC. by 4.9% in the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock valued at $112,000 after buying an additional 22 shares in the last quarter. Finally, JNBA Financial Advisors increased its stake in Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock valued at $116,000 after buying an additional 12 shares in the last quarter. Institutional investors and hedge funds own 83.63% of the company’s stock.
Shares of Allergan PLC. (NYSE:AGN) traded down 0.35% during trading on Friday, reaching $223.99. 2,006,235 shares of the company were exchanged. The firm’s 50 day moving average price is $243.31 and its 200 day moving average price is $238.68. The company has a market capitalization of $74.88 billion, a PE ratio of 6.82 and a beta of 1.16. Allergan PLC. has a one year low of $184.50 and a one year high of $256.80.
Allergan PLC. (NYSE:AGN) last announced its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The firm had revenue of $4.01 billion during the quarter, compared to analyst estimates of $3.95 billion. During the same period last year, the firm posted $3.35 EPS. The business’s revenue was up 8.8% compared to the same quarter last year. Equities research analysts forecast that Allergan PLC. will post $16.27 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be given a dividend of $0.70 per share. This represents a $2.80 annualized dividend and a dividend yield of 1.25%. The ex-dividend date of this dividend is Wednesday, August 16th. Allergan PLC.’s dividend payout ratio is presently 9.95%.
Several analysts recently issued reports on AGN shares. Citigroup Inc. reaffirmed a “focus list” rating and set a $261.27 price objective (up from $184.50) on shares of Allergan PLC. in a report on Friday, April 21st. Royal Bank Of Canada increased their price target on shares of Allergan PLC. from $279.00 to $284.00 and gave the company an “outperform” rating in a report on Wednesday, May 10th. Goldman Sachs Group, Inc. (The) downgraded shares of Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 price target for the company. in a report on Wednesday, May 10th. UBS AG reissued a “buy” rating and issued a $275.00 price target on shares of Allergan PLC. in a report on Monday, May 15th. Finally, Sanford C. Bernstein restated an “outperform” rating on shares of Allergan PLC. in a research note on Thursday, May 25th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $275.49.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.